Pierre Gianello
Director/Board Member at NYXOAH SA
Net worth: 485 663 $ as of 2024-03-30
Profile
Pierre Gianello is the founder of SYnAbs SA, which was founded in 2015.
He is currently a Director at Brussels Life Science Incubator SA and a Director at Pig For Life SA. He is also a Non-Executive Director at Nyxoah SA since 2018.
Dr. Gianello's former positions include being a Director at BruCells NV and Fetus For Life.
He was also a Professor at Katholieke Universiteit Leuven from 1997 to 2011.
Dr. Gianello holds a doctorate degree from Université Catholique de Louvain.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NYXOAH SA
0.13% | 2024-03-17 | 36,560 ( 0.13% ) | 485 663 $ | 2024-03-30 |
Pierre Gianello active positions
| Companies | Position | Start |
|---|---|---|
| NYXOAH SA | Director/Board Member | 2018-03-26 |
Brussels Life Science Incubator SA
 Brussels Life Science Incubator SA Real Estate DevelopmentFinance Brussels Life Science Incubator SA leases laboratory and medical research spaces for businesses. It offers administrative spaces, laboratory spaces, shared areas, logistics, technological and scientific, and business services. The company was founded on August 1, 2008 and is headquartered in Brussels, Belgium. | Director/Board Member | - |
Pig For Life SA
 Pig For Life SA Agricultural Commodities/MillingProcess Industries Pig For Life SA is a Belgian company that specializes in breeding pigs. The company is based in Marche-en-Famenne, Belgium. | Director/Board Member | - |
Former positions of Pierre Gianello
| Companies | Position | End |
|---|---|---|
| Katholieke Universiteit Leuven | Corporate Officer/Principal | 2010-12-31 |
| Fetus For Life | Director/Board Member | - |
SynAbs SA
 SynAbs SA BiotechnologyHealth Technology SYnAbs SA specializes in generating unique secondary monoclonal antibodies that target a variety of repertoires including mouse, human, rat, llama, rabbit, and guinea pig. The company is based in Gosselies, Belgium. The Belgian company focuses on generating highly specific therapeutic and R & D monoclonal antibodies that target difficult and poor immunogenic antigens for PK/PD, immunogenicity assays, and therapeutic applications. The company also specializes in generating monoclonal antibodies against haptens, GPCR, complex transmembrane proteins, and other difficult antigens. The company was founded in 2015 by Yannic Nizet, Pierre Gianello. The CEO is Julien Isoard. | Founder | - |
BruCells NV
 BruCells NV Pharmaceuticals: MajorHealth Technology BruCells NV develops therapeutic vaccines against cancer. The company was founded in 2001 and is headquartered in Brussels, Belgium. | Director/Board Member | - |
Training of Pierre Gianello
| Université Catholique de Louvain | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NYXOAH SA | Health Technology |
| Private companies | 5 |
|---|---|
BruCells NV
BruCells NV Pharmaceuticals: MajorHealth Technology BruCells NV develops therapeutic vaccines against cancer. The company was founded in 2001 and is headquartered in Brussels, Belgium. | Health Technology |
Brussels Life Science Incubator SA
Brussels Life Science Incubator SA Real Estate DevelopmentFinance Brussels Life Science Incubator SA leases laboratory and medical research spaces for businesses. It offers administrative spaces, laboratory spaces, shared areas, logistics, technological and scientific, and business services. The company was founded on August 1, 2008 and is headquartered in Brussels, Belgium. | Finance |
SynAbs SA
SynAbs SA BiotechnologyHealth Technology SYnAbs SA specializes in generating unique secondary monoclonal antibodies that target a variety of repertoires including mouse, human, rat, llama, rabbit, and guinea pig. The company is based in Gosselies, Belgium. The Belgian company focuses on generating highly specific therapeutic and R & D monoclonal antibodies that target difficult and poor immunogenic antigens for PK/PD, immunogenicity assays, and therapeutic applications. The company also specializes in generating monoclonal antibodies against haptens, GPCR, complex transmembrane proteins, and other difficult antigens. The company was founded in 2015 by Yannic Nizet, Pierre Gianello. The CEO is Julien Isoard. | Health Technology |
Pig For Life SA
Pig For Life SA Agricultural Commodities/MillingProcess Industries Pig For Life SA is a Belgian company that specializes in breeding pigs. The company is based in Marche-en-Famenne, Belgium. | Process Industries |
| Fetus For Life |
- Stock Market
- Insiders
- Pierre Gianello